Co-founder and Managing Director of Amkey Ventures and Eureka BioVenture Partners. Co- Founder of Pharmout Labs, Pharmdel Inc., BioKey Inc. Former Chairman of Epitomics, Inc. (acquired by Abcam Ltd.). Board member of several companies, include Renal Solution (acquired by Fresenius Medical Care), Panomics, Inc. (acquired by Affymetrics), StemCyte, etc. Ph.D. in Chemistry, State University of New York at Buffalo.
Richard Chang is the President & Managing Partner of iD TechVentures. iDT VC is an active early stage tech venture investor managing total fund size of US$300M. With more than 24 years' experience in finance and operations management, Mr. Chang involves in investment strategy and direction, has recorded 10 more successful IPO companies. Mr. Chang has worked in Acer Group for 25 years being Manager of Corp. Auditing, AVP & Controller of International Sales Division, CFO of Acer Computer International Ltd. (ACI) and GM of ACI, Taiwan. He played a key role for ACI's long term growth.
Founder and CEO Maxwell Sensors, Inc., Director of Sensor Systems at Intelligent Optical Systems, Inc., Director of Biomedical Optics at Physical Optics Corp. 52 published papers and 15 issued patents. Winston Ho served as an SPIE program committee and NIH grant review committee. MS Biochemistry and Ph.D. Biophysics from Arizona State University, and then worked as a postdoctoral fellow at Columbia University in New York and a Research Scientist at University of Arizona (Optical Science Center).
Founder and Managing Partner of GRC /GVT Capital Fund. Mr. Jen has more than 20 years of management and operational experience in venture capital and technology industry. Former Head of Corporate Investment of Quanta Group. MS from Massachusetts Institute of Technology Sloan School, BS degree in Computer Engineering from University of Missouri Columbia.
Dr. Tsao received his Ph.D. in Opto-Electronics from Tatung University in Taiwan in 2015. During his time there, he published 14 refereed papers, 22 conference papers, and 7 issued patents. Prior to working with Applied BioCode, Dr. Tsao was the Manager of Forward Electronics, Co. Ltd., an electrical component company. He also worked as a Special Advisor to the President of Genepharm Biotech Corporation. Currently he is Applied BioCode's Asian (Taiwan) Correspondent where he leads fundraising activities regarding the Taiwan market, investor relations, and arranges for Applied BioCode's lab needs in Taiwan.
Partner of iD Ventures America. Retired VP/CTO of Personal Systems Group and Computing Systems Organization at HP, Co-Leader for Enterprise Systems of HP/Compaq merger, General Manager, Singapore Networks. BS degree in EE from National Cheng-Kung University, Engineering Diploma from Philips International Institute, MS in EE from Oregon State University.
Mr. Ben C. Y. Liu, Esq. brings his legal prowess in addition to his medical technologies experience to the Applied BioCode team. His areas of expertise include Investment Portfolio Management, Intellectual Property Law, Biotech Startups, Cross-Border Investment, and Corporate Law. Awarded by National Taiwan University, he earned his Bachelor of Science in Medical Technology in 1987, his Bachelor of Law in 1992, and his Masters of Business Administration: Finance in 2002. He is currently a Ph.D. Law candidate at National Chengchi University.
Mr. Wen-Jing Tsai, CPA holds more than 28 years of experience in the realms of taxation, accounting, and finance. As a representative of the CPA Association of Taiwan, he served as an advisor to the Ministry of Finance at the Taipei National Tax Administration. Under Mr. Tsai's influence, several tax amendments and new regulations were born from The Ministry of Finance over the course of several years. He received his Bachelors of Accounting from National Taiwan University, and Masters of Accounting from National Chengchi University.